Welcome to our dedicated page for MAIA Biotechnology news (Ticker: $MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAIA Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAIA Biotechnology's position in the market.
Rhea-AI Summary
MAIA Biotechnology appoints Professor Saadettin Kilickap, M.D., an accomplished researcher, to its Scientific Advisory Board, enhancing its cancer research capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.58%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announced its participation in the 36th Annual ROTH Conference to present its lead candidate THIO, a telomere-targeting anticancer agent showing promising results in non-small cell lung cancer. The Phase 2 trial is nearing completion with strong response rates and potential FDA accelerated approval in 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces promising results of THIO and ionizing radiation combination for childhood brain cancer treatment at AACR Annual Meeting. The study shows significant decrease in cell proliferation and potent anticancer effects in treatment-resistant DIPG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Rhea-AI Summary
MAIA Biotechnology, Inc. announces positive efficacy data for the combination of THIO 180mg + cemiplimab in third-line treatment of non-small cell lung cancer (NSCLC), achieving a 38% overall response rate (ORR) which significantly exceeds the standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces progress in THIO-101 Phase 2 trial with survival and response data expected soon. The company explores various cancer indications and next-gen molecules. Shareholder Letter by CEO Vlad Vitoc details immuno-oncology candidates and pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
News
Rhea-AI Summary
MAIA Biotechnology appoints Dr. Remus Vezan, a renowned immuno-oncology leader, to its Scientific Advisory Board. Dr. Vezan's extensive experience in drug development and regulatory affairs, including FDA approvals for blockbuster products, brings valuable expertise to MAIA's clinical-stage biopharmaceutical endeavors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
Rhea-AI Summary
MAIA Biotechnology, Inc. completes enrollment in Phase 2 THIO-101 trial for advanced non-small cell lung cancer, showing promising results and potential as a new standard of care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. announces the publication of extensive work describing preclinical studies for lead candidate THIO in small cell lung cancer (SCLC) in the peer-reviewed scientific journal Nature Communications. The research demonstrates the immune-enhancing, metastasis-reducing effects of MAIA’s telomere-targeting agent THIO in several well-characterized in vitro and in vivo models of SCLC. The findings highlight a unique dual mechanism of action for THIO as a first-in-clinic telomere-targeted anticancer agent for potential treatment of SCLC. THIO has been awarded orphan drug designation (ODD) by the FDA for SCLC treatment, and the company has entered the Phase 2 planning stage for a clinical trial of THIO in SCLC along with two other cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.4%
Tags
-
Rhea-AI Summary
MAIA Biotechnology, Inc. has announced the publication of a global Patent Cooperation Treaty (PCT) application for their telomere-targeting platform, extending potential cancer therapies using dinucleotide compounds. The new patent would provide coverage through 2043 and expand the value of their innovative cancer treatment platform globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
Rhea-AI Summary
MAIA Biotechnology, Inc. announces positive interim data for THIO-101 Phase 2 trial in non-small cell lung cancer, with sustained disease control rates. The company also outlines key clinical milestones for 2024, maintaining a robust clinical pipeline in hard-to-treat cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.33%
Tags
MAIA Biotechnology, Inc.
NYSE:MAIA
MAIA Rankings
MAIA Stock Data
68.12M
14.55M
21.43%
3.9%
4.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
CHICAGO
About MAIA
maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru